Clinical trials in Delft – page 18

1 232 clinical trials in Delft, The Netherlands across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in the NetherlandsKlinischOnderzoek.nl

Delft at a glance

1 232

clinical trials

Research sites1

Quick filters

1 232 trials in Delft

Open in trial search

Non-small cell lung cancer

Recruiting

Study of zoldonrasib with daraxonrasib, pembrolizumab and chemotherapy in patients with RAS G12D-mutant non-small cell lung cancer

Registered drugNo placebo

Study of zoldonrasib with daraxonrasib, pembrolizumab and chemotherapy in patients with RAS G12D-mutant non-small cell lung cancer

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Carboplatin
Sponsor:Revolution Medicines Inc.

Contact Research Centre

IgA nephropathy

Recruiting

Study of Mezagitamab in Adults with Primary IgA Nephropathy (Berger's Disease) to Reduce Protein in Urine

Investigational

Study of Mezagitamab in Adults with Primary IgA Nephropathy (Berger's Disease) to Reduce Protein in Urine

Investigational

The Netherlands

Participants:18–64 years · 65+ years
Substances:Mezagitamab
Sponsor:Takeda Development Center Americas Inc.

Contact Research Centre

Axial spondyloarthritis+3

Recruiting

Study of Janus kinase inhibitor dose reduction in patients with rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis who have achieved low disease activity

Registered drugNo placebo

Study of Janus kinase inhibitor dose reduction in patients with rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis who have achieved low disease activity

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Baricitinib
Sponsor:Sint Maartenskliniek

Contact Research Centre

Secondary immunodeficiency

Recruiting

Study of human normal immunoglobulin and teclistamab for infection prevention in adults with multiple myeloma receiving B-cell maturation antigen therapy

Registered drugNo placebo

Study of human normal immunoglobulin and teclistamab for infection prevention in adults with multiple myeloma receiving B-cell maturation antigen therapy

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Teclistamab
Sponsor:Takeda Development Center Americas Inc.

Contact Research Centre

Osteoarthritis

Recruiting

Study of intramuscular methylprednisolone acetate to treat pain in patients with hand osteoarthritis

Registered drug

Study of intramuscular methylprednisolone acetate to treat pain in patients with hand osteoarthritis

Registered drug

The Netherlands

Participants:18–64 years · 65+ years
Substances:Sodium Chloride
Sponsor:Sint Maartenskliniek

Contact Research Centre

Hepatocellular carcinoma

Recruiting

Study of Rilvegostomig with Bevacizumab and Tremelimumab as First-line Treatment for Patients with Advanced Liver Cancer

Registered drugNo placebo

Study of Rilvegostomig with Bevacizumab and Tremelimumab as First-line Treatment for Patients with Advanced Liver Cancer

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Atezolizumab
Sponsor:AstraZeneca AB

Contact Research Centre

Non-small cell lung cancer

Recruiting

Study comparing RMC-6236 and docetaxel in previously treated patients with advanced or metastatic non-small cell lung cancer who have RAS mutations

Registered drugNo placebo

Study comparing RMC-6236 and docetaxel in previously treated patients with advanced or metastatic non-small cell lung cancer who have RAS mutations

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Daraxonrasib
Sponsor:Revolution Medicines Inc.

Contact Research Centre

Autoimmune haemolytic anaemia

Recruiting

Study of rilzabrutinib tablets compared to placebo in adults with warm autoimmune hemolytic anemia

Investigational

Study of rilzabrutinib tablets compared to placebo in adults with warm autoimmune hemolytic anemia

Investigational

The Netherlands

Participants:18–64 years · 65+ years
Substances:Rilzabrutinib
Sponsor:Sanofi-Aventis Recherche & Developpement

Contact Research Centre

COVID-19

Recruiting

Study of ibuzatrelvir alone or combined with remdesivir in adults with COVID-19 who have severely compromised immune systems

Investigational

Study of ibuzatrelvir alone or combined with remdesivir in adults with COVID-19 who have severely compromised immune systems

Investigational

The Netherlands

Participants:18–64 years · 65+ years
Substances:Ibuzatrelvir
Sponsor:Pfizer Inc.

Contact Research Centre

K-ras gene mutation+1

Recruiting

Study of MK-1084, cetuximab and mFOLFOX6 combination compared to mFOLFOX6 with or without bevacizumab for patients with KRAS G12C-mutant advanced colorectal cancer

Registered drugNo placebo

Study of MK-1084, cetuximab and mFOLFOX6 combination compared to mFOLFOX6 with or without bevacizumab for patients with KRAS G12C-mutant advanced colorectal cancer

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Bevacizumab
Sponsor:Merck Sharp & Dohme LLC

Contact Research Centre

B-cell small lymphocytic lymphoma refractory+1

Recruiting

Study of sonrotoclax plus obinutuzumab or rituximab compared to venetoclax plus rituximab in patients with relapsed or refractory chronic lymphocytic leukemia

Registered drugNo placebo

Study of sonrotoclax plus obinutuzumab or rituximab compared to venetoclax plus rituximab in patients with relapsed or refractory chronic lymphocytic leukemia

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Obinutuzumab
Sponsor:BeOne Medicines AG

Contact Research Centre

Transitional cell carcinoma

Recruiting

Study of datopotamab deruxtecan with platinum-based therapy compared to gemcitabine with platinum-based therapy in patients with advanced urothelial cancer after prior treatment

Registered drugNo placebo

Study of datopotamab deruxtecan with platinum-based therapy compared to gemcitabine with platinum-based therapy in patients with advanced urothelial cancer after prior treatment

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Carboplatin
Sponsor:Daiichi Sankyo Inc.

Contact Research Centre

Other cities in the Netherlands

The busiest research cities in the country

All 101 cities in the Netherlands

Clinical research in Delft

What the registry says about research in the country

01 Cardiovascular Research

Clinical trials focusing on cardiovascular disease management and prevention, including studies of novel treatments for atherosclerotic cardiovascular disease and innovative therapies targeting lipoprotein reduction.

Lipid Management Studies
Cardiovascular Risk Prevention
Major Adverse Cardiac Events

Research exploring both established and experimental treatments to reduce cardiovascular complications and improve patient outcomes.

02 Oncology Studies

Comprehensive research into various cancer types, with significant focus on prostate cancer, breast cancer, and blood cancers including chronic lymphocytic leukemia.

Advanced Imaging Techniques
Targeted Therapies
Treatment Combinations

Innovative approaches combining established treatments with novel therapeutic agents to enhance treatment effectiveness.

03 Women's Health

Studies addressing various aspects of women's health, including infertility treatments and management of uterine fibroids.

Reproductive Health
Gynecological Conditions
Quality of Life Studies

Research comparing different treatment modalities and their impact on patient outcomes and quality of life.

Back to the Netherlands All countries